HC Wainwright Issues Pessimistic Estimate for ENTA Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Investment analysts at HC Wainwright dropped their Q2 2025 earnings estimates for Enanta Pharmaceuticals in a report released on Tuesday, February 11th. HC Wainwright analyst E. Arce now expects that the biotechnology company will post earnings per share of ($1.42) for the quarter, down from their previous forecast of ($1.32). HC Wainwright currently has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($5.05) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q3 2025 earnings at ($1.81) EPS, Q4 2025 earnings at ($2.00) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.50) EPS, FY2027 earnings at ($9.80) EPS, FY2028 earnings at ($9.50) EPS and FY2029 earnings at ($8.15) EPS.

Several other equities research analysts also recently issued reports on the company. JMP Securities reissued a “market outperform” rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday. StockNews.com lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Robert W. Baird lowered their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Up 28.0 %

Shares of Enanta Pharmaceuticals stock opened at $7.50 on Thursday. Enanta Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $17.80. The stock has a market cap of $159.98 million, a PE ratio of -1.37 and a beta of 0.54. The business has a fifty day simple moving average of $5.75 and a 200-day simple moving average of $9.51.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Krensavage Asset Management LLC increased its position in Enanta Pharmaceuticals by 19.7% during the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after buying an additional 246,736 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Enanta Pharmaceuticals by 9.3% during the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company’s stock worth $5,348,000 after acquiring an additional 79,197 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after acquiring an additional 14,575 shares during the last quarter. State Street Corp raised its stake in shares of Enanta Pharmaceuticals by 6.4% in the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock valued at $4,662,000 after acquiring an additional 27,147 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock worth $2,524,000 after purchasing an additional 85,082 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Insider Transactions at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly bought 45,000 shares of the firm’s stock in a transaction on Wednesday, February 12th. The stock was bought at an average cost of $5.69 per share, with a total value of $256,050.00. Following the completion of the transaction, the chief executive officer now directly owns 846,638 shares of the company’s stock, valued at approximately $4,817,370.22. The trade was a 5.61 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 13.89% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.